Trailing-twelve-month (TTM) revenue is $8.25 Billion with a year-over-year growth of +2.01%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $2,042,812,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-22 |
| Q4 FY2025Period ended 2025-12-31 | $2,112,517,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-27 |
| Q1 FY2026Period ended 2026-03-31 | $2,033,999,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-23 |
| Q2 FY2026Period ended 2026-06-30 | $2,063,485,999 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $8,252,813,999 |
Current P/S: $12,407,730,965 market capitalization ÷ $8,252,813,999 TTM revenue = 1.50x.
Market capitalization source: FMP quote. Quote observed 2026-10-02T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $2.06B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-03T00:15:33.523Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2012-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20112011-12-31 · USD | FY20122012-12-31 · USD |
|---|---|---|
| Central Laboratory | $72M | $87M |
| Clinical Research | $874M | $1.0B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| IRELAND | N/A | $1.4B | $2.0B | $2.4B | $2.8B | $3.2B |
| Other Countries | $274M | N/A | N/A |
$8.25B
$8.25 Billion
+2.01%
vs. $8.09B a year ago (TTM)
+20.93%
5 Year compound annual growth rate
1 Year
+2.01%
3 Year
+1.45%
5 Year
+20.93%
10 Year
+17.76%
15 Year
+15.75%
20 Year
+16.72%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $8.25B | ($30.34M) | (0.37%) |
| 2024 | $8.28B | +$161.50M | +1.99% |
| 2023 | $8.12B | +$378.79M | +4.89% |
| 2022 | $7.74B | +$2.26B | +41.24% |
| 2021 | $5.48B | +$2.68B | +95.93% |
| 2020 |
TTM Growth
+2.01%
3-Year CAGR
+1.45%
5-Year CAGR
+20.93%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-03T00:15:33.523Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-02.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $943M |
| N/A |
| Rest Of Europe | N/A | N/A | N/A | $1.6B | $1.6B | $1.6B |
|---|
| Rest of World | N/A | N/A | N/A | N/A | N/A | $952M |
|---|
| UNITED STATES | $926M | $2.6B | $3.6B | $3.3B | $3.0B | $2.5B |
|---|
| $2.80B |
| ($8.55M) |
| (0.30%) |
| 2019 | $2.81B | +$210.06M | +8.09% |
| 2018 | $2.60B | +$837.34M | +47.62% |
| 2017 | $1.76B | +$91.95M | +5.52% |
| 2016 | $1.67B | +$91.51M | +5.81% |
